Outcome	O
Measures	O

The	O
primary	O
endpoint	O
was	O
the	O
duration	B-PrimaryOutcome
of	I-PrimaryOutcome
viral	I-PrimaryOutcome
shedding	I-PrimaryOutcome
,	O
which	O
was	O
defined	O
as	O
the	O
time	B-OutcomeDefinition
from	I-OutcomeDefinition
randomization	I-OutcomeDefinition
to	I-OutcomeDefinition
the	I-OutcomeDefinition
first	I-OutcomeDefinition
negative	I-OutcomeDefinition
nucleic	I-OutcomeDefinition
acid	I-OutcomeDefinition
test	I-OutcomeDefinition
of	I-OutcomeDefinition
5	I-OutcomeDefinition
consecutive	I-OutcomeDefinition
RT	I-OutcomeDefinition
-	I-OutcomeDefinition
PCR	I-OutcomeDefinition
results	I-OutcomeDefinition
.	O

Other	O
clinical	O
outcomes	O
included	O
clinical	B-OtherOutcome
status	I-OtherOutcome
(	I-OtherOutcome
ie	I-OtherOutcome
,	I-OtherOutcome
progressive	I-OtherOutcome
rate	I-OtherOutcome
to	I-OtherOutcome
severe	I-OtherOutcome
illness	I-OtherOutcome
)	I-OtherOutcome
,	O
syndromes	B-OtherOutcome
,	O
peripheral	B-OtherOutcome
blood	I-OtherOutcome
cells	I-OtherOutcome
,	O
and	O
biochemical	B-OtherOutcome
parameters	I-OtherOutcome
,	O
C	B-OtherOutcome
-	I-OtherOutcome
reactive	I-OtherOutcome
protein	I-OtherOutcome
and	I-OtherOutcome
inflammatory	I-OtherOutcome
cytokines	I-OtherOutcome
,	O
and	O
length	B-OtherOutcome
of	I-OtherOutcome
hospital	I-OtherOutcome
stay	I-OtherOutcome
.	O

Safety	O
outcomes	O
included	O
adverse	B-OtherOutcome
events	I-OtherOutcome
(	I-OtherOutcome
AEs	I-OtherOutcome
)	I-OtherOutcome
that	O
occurred	O
during	O
treatment	O
,	O
serious	B-OtherOutcome
AEs	I-OtherOutcome
,	O
and	O
premature	B-OtherOutcome
discontinuation	I-OtherOutcome
of	I-OtherOutcome
treatment	I-OtherOutcome
.	O

